When will this idiot Vaccine leadership realize Zostavax is a dud and Pneumovax 23 is on the decline. Disbanding the pharmacy vaccine group, deploying that group to call on non Zostavax users and hiring a contract sales force to also call on non Zostavax users has yielded no growth. No more incentives for hospitals to have Pneumococcal vaccination protocols and better reimbursement for P13 has also killed P23. Newsflash, there is no untapped potential in the adult Vaccine market!!!!!! The pediatric Vaccine market is saving the division as well as the company by bringing in several billions of dollars yet leadership leaves that market wide open for GSK to explore.